{
  "id": 14912611,
  "title": "Solara Active Pharma Sciences Ltd Reports ₹28.46 Crore Consolidated Profit In Q2",
  "url": "https://urgent.news/2026/10/16/solara-active-pharma-sciences-ltd-reports-28-46-crore-consolidated",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-16T08:13:52.000Z",
  "source": {
    "name": "Free Press Journal",
    "slug": "free-press-journal",
    "url": "https://www.freepressjournal.in/business/solara-active-pharma-sciences-ltd-reports-2846-crore-consolidated-profit-in-q2"
  },
  "original_language": "en",
  "account": "Mumbai-based Solara Active Pharma Sciences Ltd announced a strong recovery in its financial performance for the second quarter of 2026. The company reported a consolidated net profit after tax of ₹28.46 crore, a marked improvement from a net loss of ₹10.10 crore in the same quarter last year. Revenue from operations saw a significant surge of 33.10%, reaching ₹417.34 crore compared to ₹313.54 crore in the same period the previous year.\n\nLooking ahead to the half-year period, Solara Active Pharma's consolidated net profit after tax stood at ₹44.77 crore, a substantial leap from just ₹0.42 crore in the corresponding half-year of the previous year. Total revenue for the six months increased to ₹802.17 crore, up from ₹634.16 crore.\n\nDespite the revenue growth, the company's total expenses rose for the quarter to ₹384.92 crore, up from ₹324.13 crore in the previous year's quarter. For the half-year, total expenses amounted to ₹752.90 crore, compared to ₹633.74 crore in the prior year's half-year.\n\nEarnings per share (EPS) also improved significantly. For the quarter, consolidated basic EPS was ₹5.92, compared to a negative ₹2.36 in the same quarter last year. For the half-year, basic EPS was ₹9.49, a major improvement from ₹0.10 in the prior year's half-year.\n\nThe company disclosed an exceptional loss of ₹4.50 crore for both the quarter and half-year ended 30 September 2026. This loss is primarily due to the sale of capital work in progress associated with the mothballed Vizag plant since the 2023-24 financial year.\n\nThe Maharashtra FDA recently canceled Cipla Pharma & Life Sciences' Pune warehouse drug licenses due to multiple lapses. The board meeting to approve the unaudited financial results commenced at 12:30 PM and concluded at 01:20 PM on 16 October 2026. Both standalone and consolidated results were approved along with the Limited Review Report from Deloitte Haskins & Sells, Chartered Accountants.\n\nDespite accumulated losses of ₹274.16 crore as of 30 September 2026, management remains confident in meeting its obligations. This optimistic outlook is based on projected growth in revenues and margins, enhanced business performance, and anticipated renewal of working capital facilities.",
  "summary": "Mumbai: Solara Active Pharma Sciences Ltd on Friday reported a consolidated net profit after tax of ₹28.46 crore for the quarter ended 30 September 2026, compared to a net loss of ₹10.10 crore in the corresponding quarter of the previous financial year. The company's revenue from operations rose by 33.10% to ₹417.34 crore for the quarter, up from ₹313.54 crore in the year-ago period. Half-Year…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}